Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Tjalf Ziemssen; Ann D. Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F. Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M.J. Uitdehaag; Wijmeersch B Van; Zia Choudhry; Nadia Daizadeh; Barry A. Singer

doi:10.1007/s40263-020-00749-x

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Tjalf Ziemssen^*, Ann D. Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Jeremy Hobart, Samuel F. Hunter, Christopher LaGanke, Volker Limmroth, Daniel Pelletier, Carlo Pozzilli, Sven Schippling, Livia Sousa, Anthony Traboulsee, Bernard M.J. Uitdehaag, Wijmeersch B Van, Zia Choudhry, Nadia Daizadeh, Barry A. Singer

^*Corresponding author for this work

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

7 Downloads (Pure)

Original language	English
Number of pages	0
Journal	CNS Drugs
Volume	0
Issue number	0
Early online date	24 Jul 2020
DOIs	https://doi.org/10.1007/s40263-020-00749-x
Publication status	Published - 24 Jul 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40263-020-00749-x

Ziemssen CARE-MS 9y HAD manuscript 17June2020 Author Approval

Cite this

Ziemssen, T., Bass, A. D., Berkovich, R., Comi, G., Eichau, S., Hobart, J., Hunter, S. F., LaGanke, C., Limmroth, V., Pelletier, D., Pozzilli, C., Schippling, S., Sousa, L., Traboulsee, A., Uitdehaag, B. M. J., Van, W. B., Choudhry, Z., Daizadeh, N., & Singer, B. A. (2020). Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs, 0(0). https://doi.org/10.1007/s40263-020-00749-x

@article{a7da91fe405047469c7ade0782adb44d,

title = "Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study",

author = "Tjalf Ziemssen and Bass, {Ann D.} and Regina Berkovich and Giancarlo Comi and Sara Eichau and Jeremy Hobart and Hunter, {Samuel F.} and Christopher LaGanke and Volker Limmroth and Daniel Pelletier and Carlo Pozzilli and Sven Schippling and Livia Sousa and Anthony Traboulsee and Uitdehaag, {Bernard M.J.} and Van, {Wijmeersch B} and Zia Choudhry and Nadia Daizadeh and Singer, {Barry A.}",

year = "2020",

month = jul,

day = "24",

doi = "10.1007/s40263-020-00749-x",

language = "English",

volume = "0",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis International Ltd",

number = "0",

}

Ziemssen, T, Bass, AD, Berkovich, R, Comi, G, Eichau, S, Hobart, J, Hunter, SF, LaGanke, C, Limmroth, V, Pelletier, D, Pozzilli, C, Schippling, S, Sousa, L, Traboulsee, A, Uitdehaag, BMJ, Van, WB, Choudhry, Z, Daizadeh, N & Singer, BA 2020, 'Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study', CNS Drugs, vol. 0, no. 0. https://doi.org/10.1007/s40263-020-00749-x

TY - JOUR

T1 - Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

AU - Ziemssen, Tjalf

AU - Bass, Ann D.

AU - Berkovich, Regina

AU - Comi, Giancarlo

AU - Eichau, Sara

AU - Hobart, Jeremy

AU - Hunter, Samuel F.

AU - LaGanke, Christopher

AU - Limmroth, Volker

AU - Pelletier, Daniel

AU - Pozzilli, Carlo

AU - Schippling, Sven

AU - Sousa, Livia

AU - Traboulsee, Anthony

AU - Uitdehaag, Bernard M.J.

AU - Van, Wijmeersch B

AU - Choudhry, Zia

AU - Daizadeh, Nadia

AU - Singer, Barry A.

PY - 2020/7/24

Y1 - 2020/7/24

U2 - 10.1007/s40263-020-00749-x

DO - 10.1007/s40263-020-00749-x

M3 - Article

SN - 1172-7047

VL - 0

JO - CNS Drugs

JF - CNS Drugs

IS - 0

ER -